NOVARTIS AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 95.74 CHF | -1.01% |
|
-0.20% | +12.76% |
| 06:12am | Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector | MT |
| Jul. 01 | Amneal Pharmaceuticals to Develop Omalizumab Biosimilar for Allergy Treatments | MT |
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
2024-07-18
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
107
USD
Average target price
110.3
USD
Spread / Average Target
+3.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.76% | 218B | |
| +56.86% | 823B | |
| +44.56% | 641B | |
| -6.57% | 352B | |
| +17.32% | 324B | |
| +9.94% | 301B | |
| +15.74% | 241B | |
| +1.35% | 223B | |
| +7.98% | 167B | |
| -1.98% | 160B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Fitch Affirms Novartis Ratings on Leading Position in Innovative Pharmaceutical Sector
